Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - CON

V. Cottin (Lyon, France)

Source: Virtual Congress 2020 – When the lung gets stiff
Session: When the lung gets stiff
Session type: Journal session
Number: 4822

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Cottin (Lyon, France). Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - CON. Virtual Congress 2020 – When the lung gets stiff

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - PRO
Source: Virtual Congress 2020 – When the lung gets stiff
Year: 2020


IPF: a distinct clinical entity?
Source: International Congress 2017 – State of the art session: "Interstitial lung disease and pulmonary vascular diseases"
Year: 2017


Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?
Source: Eur Respir J, 55 (6) 2000811; 10.1183/13993003.00811-2020
Year: 2020



Making clinical sense of the explosion in biologics - which drug for which patient and why?
Source: International Congress 2019 – PG10 Severe asthma in adults: systematic assessment and biological treatment
Year: 2019


The pathogenesis of IPF: what is the latest paradigm?
Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis
Year: 2019

Respirologists‘ perception versus patient reality: A Canadian perspective on COPD
Source: Annual Congress 2011 - Integrated care and telehealth in primary care
Year: 2011

The progressive fibrotic phenotype in ILDs: can it be reliably recognised at baseline evaluation?
Source: International Congress 2019 – Lumping and splitting of fibrotic interstitial lung diseases
Year: 2019


Facing the challenges of self-management in COPD: how do people adapt to the disease, its symptoms and resulting limitations?
Source: Eur Respir J 2005; 26: Suppl. 49, 310s
Year: 2005

Is our approach to basic research right? Pitfalls and successes: what is the way forward?
Source: ERS Research Seminar 2016
Year: 2016

What do we need from our patients? - the clinician's point of view
Source: International Congress 2014 – PG17 Lung cancer: the issue with the tissue
Year: 2014




Early diagnosis of COPD: myth or a true perspective
Source: Eur Respir Rev, 29 (158) 200131; 10.1183/16000617.0131-2020
Year: 2020



MDR-/XDR-TB: what are the unresolved problems in the clinical management?
Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET)
Year: 2012



Non Specific Interstitial Pneumonia and features of connective tissue disease:what are the consequences of a different point of view?
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis:  mechanistic insights and prognostic markers
Year: 2018


Large trials, new knowledge: the changing face of COPD management
Source: Eur Respir J 2015; 45: 1692-1703
Year: 2015